Aβ Imaging: feasible, pertinent, and vital to progress in Alzheimer’s disease

[1]  Xiaojing Sui,et al.  Cerebrospinal fluid biomarkers of Alzheimer’s disease , 2014, Neuroscience Bulletin.

[2]  Bradford C. Dickerson,et al.  Regional Expansion of Hypometabolism in Alzheimer's Disease Follows Amyloid Deposition with Temporal Delay , 2012, Biological Psychiatry.

[3]  Peiying Liu,et al.  Comparison of relative cerebral blood flow maps using pseudo‐continuous arterial spin labeling and single photon emission computed tomography , 2012, NMR in biomedicine.

[4]  A. Alavi,et al.  Amyloid-β imaging with PET in Alzheimer’s disease: is it feasible with current radiotracers and technologies? , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[5]  W. Klunk.  Amyloid imaging as a biomarker for cerebral β-amyloidosis and risk prediction for Alzheimer dementia , 2011, Neurobiology of Aging.

[6]  J. Trojanowski,et al.  Association between in vivo fluorine 18-labeled flutemetamol amyloid positron emission tomography imaging and in vivo cerebral cortical histopathology. , 2011, Archives of neurology.

[7]  Kewei Chen,et al.  Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. , 2011, Archives of neurology.

[8]  D. Selkoe,et al.  Resolving controversies on the path to Alzheimer's therapeutics , 2011, Nature Medicine.

[9]  S. DeKosky,et al.  Precuneus amyloid burden is associated with reduced cholinergic activity in Alzheimer disease , 2011, Neurology.

[10]  H. Gertz,et al.  Individualized quantification of brain β-amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer’s disease and healthy controls , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[11]  John Seibyl,et al.  Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study , 2011, The Lancet Neurology.

[12]  Keith A. Johnson,et al.  Neuronal dysfunction and disconnection of cortical hubs in non-demented subjects with elevated amyloid burden , 2011, Alzheimer's & Dementia.

[13]  A. Vighetto,et al.  In vivo demonstration of amyloid burden in posterior cortical atrophy: a case series with PET and CSF findings , 2011, Journal of Neurology.

[14]  D. Selkoe,et al.  Soluble amyloid β-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration , 2011, Proceedings of the National Academy of Sciences.

[15]  Keith A. Johnson,et al.  Amyloid-β Associated Cortical Thinning in Clinically Normal Elderly , 2011, Annals of neurology.

[16]  M. Modat,et al.  The importance of appropriate partial volume correction for PET quantification in Alzheimer’s disease , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[17]  R. Coleman,et al.  Use of florbetapir-PET for imaging beta-amyloid pathology. , 2011, JAMA.

[18]  C. Rowe,et al.  Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease , 2011, Annals of neurology.

[19]  A. Nordberg,et al.  Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer’s disease , 2010, Brain : a journal of neurology.

[20]  Stephen W. Scheff,et al.  Mild cognitive impairment: pathology and mechanisms , 2011, Acta Neuropathologica.

[21]  Keith A. Johnson,et al.  Spatial relation between microbleeds and amyloid deposits in amyloid angiopathy , 2010, Annals of neurology.

[22]  E. Salmon,et al.  18F‐flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial , 2010, Annals of neurology.

[23]  C. Rowe,et al.  Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging , 2010, Neurobiology of Aging.

[24]  H. Hall,et al.  [(11)C]PIB-amyloid binding and levels of Abeta40 and Abeta42 in postmortem brain tissue from Alzheimer patients , 2010, Alzheimer's & Dementia.

[25]  James Robert Brašić,et al.  In Vivo Imaging of Amyloid Deposition in Alzheimer Disease Using the Radioligand 18F-AV-45 (Flobetapir F 18) , 2010, Journal of Nuclear Medicine.

[26]  H. Levine,et al.  Molecular polymorphism of Aβ in Alzheimer's disease , 2010, Neurobiology of Aging.

[27]  C. Rowe,et al.  Relationship between atrophy and β‐amyloid deposition in Alzheimer disease , 2010, Annals of neurology.

[28]  C. Jack,et al.  Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.

[29]  N. Cairns,et al.  In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia , 2010, Neurology.

[30]  A. Fagan,et al.  APOE predicts amyloid‐beta but not tau Alzheimer pathology in cognitively normal aging , 2010, Annals of neurology.

[31]  C. Rowe,et al.  11C-PiB PET ABri imaging in Worster-Drought syndrome (familial British dementia): a case report. , 2010, Journal of Alzheimer's disease : JAD.

[32]  K. Ishii,et al.  Posterior cortical atrophy with [11C] Pittsburgh compound B accumulation in the primary visual cortex , 2010, Journal of Neurology.

[33]  Mark A Mintun,et al.  Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report. , 2009, Archives of neurology.

[34]  Masanori Nakagawa,et al.  High striatal amyloid beta-peptide deposition across different autosomal Alzheimer disease mutation types. , 2009, Archives of neurology.

[35]  Nick C Fox,et al.  Conversion of amyloid positive and negative MCI to AD over 3 years , 2009, Neurology.

[36]  C. Jack,et al.  Comparison of 18F-FDG and PiB PET in Cognitive Impairment , 2009, Journal of Nuclear Medicine.

[37]  Jeffrey A. James,et al.  Amyloid imaging in mild cognitive impairment subtypes , 2009, Annals of neurology.

[38]  Bengt Långström,et al.  [11C]PIB-amyloid binding and levels of Aβ40 and Aβ42 in postmortem brain tissue from Alzheimer patients , 2009, Neurochemistry International.

[39]  G. Alexander,et al.  Fibrillar amyloid-β burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease , 2009, Proceedings of the National Academy of Sciences.

[40]  C. Rowe,et al.  11C-PiB PET studies in typical sporadic Creutzfeldt–Jakob disease , 2009, Journal of Neurology, Neurosurgery & Psychiatry.

[41]  C. Rowe,et al.  Characterization of PiB Binding to White Matter in Alzheimer Disease and Other Dementias , 2009, Journal of Nuclear Medicine.

[42]  M. Mintun,et al.  Alzheimer disease and cognitive reserve: variation of education effect with carbon 11-labeled Pittsburgh Compound B uptake. , 2008, Archives of neurology.

[43]  Jeffrey A. James,et al.  Frequent amyloid deposition without significant cognitive impairment among the elderly. , 2008, Archives of neurology.

[44]  Sakari Savolainen,et al.  Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B. , 2008, Archives of neurology.

[45]  H. Engler,et al.  PET imaging of amyloid deposition in patients with mild cognitive impairment , 2008, Neurobiology of Aging.

[46]  C. Rowe,et al.  Amyloid load in Parkinson’s disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.

[47]  A. Paetau,et al.  PET amyloid ligand [11C]PIB uptake shows predominantly striatal increase in variant Alzheimer's disease. , 2008, Brain : a journal of neurology.

[48]  Andrew Lockhart,et al.  In vitro high affinity α-synuclein binding sites for the amyloid imaging agent PIB are not matched by binding to Lewy bodies in postmortem human brain , 2008, Journal of neurochemistry.

[49]  S. DeKosky,et al.  Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease , 2008, Brain : a journal of neurology.

[50]  C. Jack,et al.  11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. , 2008, Brain : a journal of neurology.

[51]  Yasuyoshi Watanabe,et al.  A new amyloid β variant favoring oligomerization in Alzheimer's‐type dementia , 2008, Annals of neurology.

[52]  C. Rowe,et al.  Imaging of amyloid β in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism , 2008, The Lancet Neurology.

[53]  Markus Schwaiger,et al.  Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer’s disease , 2008, NeuroImage.

[54]  C. Jack,et al.  11 C PiB and structural MRI provide complementary information in imaging of Alzheimer ’ s disease and amnestic mild cognitive impairment , 2008 .

[55]  S. Aalto,et al.  Posterior cortical atrophy: a rare form of dementia with in vivo evidence of amyloid-beta accumulation. , 2008, Journal of Alzheimer's disease : JAD.

[56]  Tetsuya Suhara,et al.  Longitudinal, Quantitative Assessment of Amyloid, Neuroinflammation, and Anti-Amyloid Treatment in a Living Mouse Model of Alzheimer's Disease Enabled by Positron Emission Tomography , 2007, The Journal of Neuroscience.

[57]  V. Libri,et al.  PIB is a non-specific imaging marker of amyloid-beta (Abeta) peptide-related cerebral amyloidosis. , 2007, Brain : a journal of neurology.

[58]  C. Rowe,et al.  In Vitro Characterization of Pittsburgh Compound-B Binding to Lewy Bodies , 2007, The Journal of Neuroscience.

[59]  Keith A. Johnson,et al.  Imaging of amyloid burden and distribution in cerebral amyloid angiopathy , 2007, Annals of neurology.

[60]  C. Rowe,et al.  Evaluating atypical dementia syndromes using positron emission tomography with carbon 11 labeled Pittsburgh Compound B. , 2007, Archives of neurology.

[61]  K. Jellinger,et al.  Topographical distribution of cerebral amyloid angiopathy and its effect on cognitive decline are influenced by Alzheimer disease pathology , 2007, Journal of the Neurological Sciences.

[62]  Yu-Te Wu,et al.  Classification of hemodynamics from dynamic-susceptibility-contrast magnetic resonance (DSC-MR) brain images using noiseless independent factor analysis , 2007, Medical Image Anal..

[63]  Matthew P. Frosch,et al.  Plasma A&bgr; Levels Do Not Reflect Brain A&bgr; Levels , 2007 .

[64]  Keith A. Johnson,et al.  Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. , 2007, Archives of neurology.

[65]  B. Hyman,et al.  Plasma Abeta levels do not reflect brain Abeta levels. , 2007, Journal of neuropathology and experimental neurology.

[66]  H. Engler,et al.  Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. , 2006, Brain : a journal of neurology.

[67]  Keith A. Johnson,et al.  P2-366 Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees , 2006, Alzheimer's & Dementia.

[68]  Y. Stern.  Cognitive Reserve and Alzheimer Disease , 2006, Alzheimer disease and associated disorders.

[69]  P. Whitehouse,et al.  Mild cognitive impairment , 2006, Lancet.

[70]  S. DeKosky,et al.  Binding of the Positron Emission Tomography Tracer Pittsburgh Compound-B Reflects the Amount of Amyloid-β in Alzheimer's Disease Brain But Not in Transgenic Mouse Brain , 2005, The Journal of Neuroscience.

[71]  S. DeKosky,et al.  Kinetic Modeling of Amyloid Binding in Humans using PET Imaging and Pittsburgh Compound-B , 2005, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[72]  Michael V. Green,et al.  PET imaging of brain with the β-amyloid probe, [11C]6-OH-BTA-1, in a transgenic mouse model of Alzheimer’s disease , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[73]  W. Klunk,et al.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.

[74]  W. Klunk,et al.  Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. , 2003, Journal of medicinal chemistry.

[75]  William E. Klunk,et al.  The Binding of 2-(4′-Methylaminophenyl)Benzothiazole to Postmortem Brain Homogenates Is Dominated by the Amyloid Component , 2003, The Journal of Neuroscience.

[76]  A. Alavi,et al.  Use of a corrected standardized uptake value based on the lesion size on CT permits accurate characterization of lung nodules on FDG-PET , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[77]  H. Braak,et al.  Phases of Aβ-deposition in the human brain and its relevance for the development of AD , 2002, Neurology.

[78]  Murray Grossman,et al.  Quantitative neurohistological features of frontotemporal degeneration , 2000, Neurobiology of Aging.

[79]  K. Davis,et al.  Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. , 2000, JAMA.

[80]  J. Trojanowski,et al.  Editorial on Consensus Recommendations for the Postmortem Diagnosis of Alzheimer Disease from the National Institute on Aging and the Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer Disease , 1997, Journal of neuropathology and experimental neurology.

[81]  H. Moldofsky,et al.  Regional differences in technetium-99m-ECD clearance on brain SPECT in healthy subjects. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[82]  John Q. Trojanowski,et al.  Consensus Recommendations for the Postmortem Diagnosis of Alzheimer’s Disease , 1997, Neurobiology of Aging.

[83]  M. Bobinski,et al.  Frequency of Stages of Alzheimer-Related Lesions in Different Age Categories , 1997, Neurobiology of Aging.

[84]  Alistair Burns,et al.  Diagnosis of Alzheimer's Disease , 1997, International Psychogeriatrics.

[85]  P. Schuck,et al.  Kinetics of ligand binding to receptor immobilized in a polymer matrix, as detected with an evanescent wave biosensor. I. A computer simulation of the influence of mass transport. , 1996, Biophysical journal.

[86]  C. Clark,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1990, Neurology.

[87]  G. V. Van Hoesen,et al.  The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. , 1991, Cerebral cortex.

[88]  T. Hutchens,et al.  Ligand‐binding properties of estrogen receptor proteins after interaction with surface‐immobilized Zn(II) ions: Evidence for localized surface interactions and minimal conformational changes , 1990, Journal of molecular recognition : JMR.

[89]  R. Mohs,et al.  Consortium to establish a registry for Alzheimer's disease (CERAD) clinical and neuropsychological assessment of Alzheimer's disease. , 2002, Psychopharmacology bulletin.

[90]  H. Tsunoo,et al.  A ligand-receptor binding assay by receptor immobilization. , 1988, Analytical biochemistry.

[91]  C. Filley.  Diagnosis of Alzheimer's disease. , 1988, Colorado medicine.

[92]  Glenner Gg.  Alzheimer's disease. The commonest form of amyloidosis. , 1983, Archives of pathology & laboratory medicine.

[93]  G. Glenner.  Alzheimer's disease. The commonest form of amyloidosis. , 1983, Archives of pathology & laboratory medicine.

[94]  M. Roth,et al.  The Association Between Quantitative Measures of Dementia and of Senile Change in the Cerebral Grey Matter of Elderly Subjects , 1968, British Journal of Psychiatry.